Paratek Pharmaceuticals, Inc.

Greetings and welcome to the Paratech Pharmaceuticals full year 2021 earnings call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Sarah Higgins, Vice President of Finance, Controller, and Principal Accounting Officer. Thank you.

You may begin.

Good morning and welcome to Paratex year-end 2021 earnings and corporate update conference call. A press release of the company's financial results was issued earlier today and we have also posted slides on our website to which we will refer on this call. Both can be found at www.paratexpharma.com. Participants on today's call are Evan Lowe, Chief Executive Officer, Adam Woodrow, President and Chief Commercial Officer, and Randy Brenner, Chief Development and Regulatory Officer. Michael Bingham, Executive Chairman, and I will also be available for questions. Before I turn the call over to Evan, I would also like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. Evan?